Loading clinical trials...
Loading clinical trials...
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France
Start Date
January 29, 2018
Primary Completion Date
July 17, 2020
Completion Date
July 1, 2025
Last Updated
March 29, 2021
135
ACTUAL participants
Blood sample collection
PROCEDURE
Biopsy collection
PROCEDURE
Lead Sponsor
Institut Paoli-Calmettes
Collaborators
NCT05529069
NCT05442515
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions